Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02237729 · ClinicalTrials.gov registry record · Phase 1
A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects (REFLECTIONS B538-07))
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 362
- Enrollment target
NCT02237729 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 362 participants.
The verdict
NCT02237729, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 362 participants
- Enrollment target
Study Summary
This is a Phase 1, double blind (sponsor open), randomized (1:1:1), parallel group, 3 arm, single dose comparative PK study of adalimumab Pfizer and adalimumab sourced from the US and EU administered subcutaneously (SC) to healthy male and female volunteers
Interventions
- BIOLOGICAL PF-06410293
- BIOLOGICAL Adalimumab-US
- BIOLOGICAL Adalimumab-EU
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 362 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02237729
The ClinicalTrials.gov registry entry for NCT02237729 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 362 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which PF-06410293 is the first listed.
NCT02237729 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02237729 about?
NCT02237729 is a clinical study titled "A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects (REFLECTIONS B538-07))". This is a Phase 1, double blind (sponsor open), randomized (1:1:1), parallel group, 3 arm, single dose comparative PK study of adalimumab Pfizer and adalimumab sourced from the US and EU administered subcutaneously (SC) to healthy male and female volunteers
What is the current status of trial NCT02237729?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 362 participants. The study started on 2014-09. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02237729?
The interventions under investigation include: PF-06410293 (BIOLOGICAL), Adalimumab-US (BIOLOGICAL), Adalimumab-EU (BIOLOGICAL).
Who is sponsoring clinical trial NCT02237729?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.